Menu
Search
|

Menu

Close
X

X T L Biopharmaceuticals Ltd XTLB.OQ (NASDAQ Stock Exchange Capital Market)

2.57 USD
+0.06 (+2.39%)
As of Oct 19
chart
Previous Close 2.51
Open 2.51
Volume 417
3m Avg Volume 3,699
Today’s High 2.57
Today’s Low 2.42
52 Week High 3.91
52 Week Low 1.58
Shares Outstanding (mil) 5.14
Market Capitalization (mil) 13.38
Forward P/E --
Dividend (Yield %) -- ( -- )

LATEST NEWS

ADVERTISEMENT

RECOMMENDATION

No Data Available
Sell Hold Buy

KEY STATS

Revenue (mm, USD)
FY18
0
FY17
0
FY16
0
FY15
0
EPS (USD)
FY18
0.002
FY17
-0.003
FY16
-0.030
FY15
-0.056
*Note: Units in Millions of U.S. Dollars
**Note: Units in U.S. Dollars

KEY RATIOS

Price to Earnings (TTM)
vs sector
--
33.64
Price to Sales (TTM)
vs sector
--
5.83
Price to Book (MRQ)
vs sector
0.67
4.89
Price to Cash Flow (TTM)
vs sector
--
22.92
Total Debt to Equity (MRQ)
vs sector
--
17.18
LT Debt to Equity (MRQ)
vs sector
--
12.76
Return on Investment (TTM)
vs sector
-70.95
14.27
Return on Equity (TTM)
vs sector
-125.01
15.99

EXECUTIVE LEADERSHIP

Shlomo Shalev Spokone
Chairman of the Board, Since 2015
Salary: --
Bonus: --
Joshua Levine
Chief Executive Officer, Since 2013
Salary: --
Bonus: --
Ronen Twito
Deputy Chief Executive Officer, Chief Financial Officer, Since 2013
Salary: --
Bonus: --
Moshe Mittelman
Chief Medical Officer, Since 2010
Salary: --
Bonus: --
Daphna Paran
Medical Director, Since 2016
Salary: --
Bonus: --

COMPANY PROFILE

Sector: Healthcare
Industry: Biotechnology & Medical Research
Address:

5 HaCharoshet St.
RA'ANANA     4365603

Phone: +9729.9557080

XTL Biopharmaceuticals Ltd. is a biopharmaceutical company. The Company focuses on the acquisition and development of pharmaceutical drugs for the treatment of medical needs. Its products include hCDR1 and Recombinant Human Erythropoietin (rHuEPO). hCDR1 is a Phase II-ready asset compound, working through a mechanism of action, for the treatment of Systemic Lupus Erythematosus (SLE). hCDR1 is a synthetic peptide that includes approximately 20 amino-acid residues. rHuEPO, a known agent for anemia, is being developed to prolong the survival of patients with advanced multiple myeloma (MM). rHuEPO is used in clinical practice for the treatment of various anemias, including anemia of kidney disease and cancer-related anemia.

SPONSORED STORIES